Résultats de la recherche - Kerstin Trunzer
- Résultat(s) 1 - 8 résultats de 8
-
1
Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Ca... par Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec, S. Curescu, Raimundas Sakalauskas, Georgy M. Manikhas, Julien Mazières, Renaud Whittom, Carol Ward, Karen Mayne, Kerstin Trunzer, Federico Cappuzzo
Publié 2011Artigo -
2
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-c... par Jennifer Moriatis Wolf, Åslaug Helland, In‐Jae Oh, M.R. Migliorino, Rafał Dziadziuszko, Anna Wrona, Javier de Castro, Julien Mazières, Frank Griesinger, M. Chlistalla, Andrés F. Cardona, Thorsten Ruf, Kerstin Trunzer, Vlatka Smoljanović, Silvia Novello
Publié 2022Artigo -
3
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung can... par Andrea Ardizzoni, Sérgio Jobim Azevedo, Belén Rubio‐Viqueira, Delvys Rodríguez‐Abreu, Jorge Alatorre-Alexander, Hans J.M. Smit, Jinming Yu, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Andrés F. Cardona, Pablo Diego Perez-Moreno, Tom Newsom‐Davis
Publié 2021Artigo -
4
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation par Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Søren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Publié 2011Artigo -
5
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma par Mario E. Lacouture, Madeleine Duvic, Axel Hauschild, Víctor G. Prieto, Caroline Robert, Dirk Schadendorf, Caroline C. Kim, Christopher McCormack, Patricia L. Myskowski, Olivia Spleiss, Kerstin Trunzer, Fei Su, B. Nelson, K. B. Nolop, Joseph F. Grippo, Richard J. Lee, Matthew J. Klimek, James L. Troy, Andrew K. Joe
Publié 2013Artigo -
6
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study par Grant A. McArthur, Paul B. Chapman, Caroline Robert, James Larkin, John B.A.G. Haanen, Reinhard Dummer, Antoni Ribas, David Hogg, Omid Hamid, Paolo A. Ascierto, Claus Garbe, Alessandro Testori, Michele Maio, Paul Lorigan, Célèste Lebbé, Thomas Jouary, Dirk Schadendorf, S. O'Day, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dréno, Jeffrey A. Sosman, Keith T. Flaherty, Ming Yin, Ivor Caro, Suzanne Cheng, Kerstin Trunzer, Axel Hauschild
Publié 2014Artigo -
7
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma par Kerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, René González, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Kevin B. Kim, Jeffrey S. Weber, Peter Hersey, Georgina V. Long, Donald P. Lawrence, Patrick A. Ott, Ravi K. Amaravadi, Karl D. Lewis, Igor Puzanov, Roger S. Lo, Astrid Koehler, Mark Kockx, Olivia Spleiss, Annette Schell-Steven, Houston Gilbert, Louise Cockey, Gideon Bollag, Richard J. Lee, Andrew K. Joe, Jeffrey A. Sosman, Antoni Ribas
Publié 2013Artigo -
8
<i>RAS</i>Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors par Fei Su, Amaya Virós, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis‐Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew J. Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noé, Maryou Lambros, Felipe C. Geyer, Nathalie Dhomen, Ion Niculescu‐Duvaz, Alfonso Zambon, Dan Niculescu‐Duvaz, Natasha Preece, Lídia Robert, Nicholas Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, K. B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, René González, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas, Richard Marais
Publié 2012Artigo
Outils de recherche:
Sujets similaires
Internal medicine
Medicine
Cancer
Cancer research
Melanoma
Metastatic melanoma
Vemurafenib
KRAS
Oncology
Biology
Kinase
Lung cancer
MAPK/ERK pathway
Adverse effect
Chemotherapy
Colorectal cancer
Confidence interval
Environmental health
Gene
Genetics
Hazard ratio
Mutation
Neuroblastoma RAS viral oncogene homolog
Phosphorylation
Population
V600E
ALK inhibitor
Alectinib
Anaplastic lymphoma kinase
Atezolizumab